Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-targeted dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Shenzhen People's Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
EBV-targeted dendritic cell vaccine is an autologous cellular immunotherapy designed to treat Epstein-Barr virus (EBV)-associated malignancies, such as EBV-positive nasopharyngeal carcinoma. The vaccine is prepared by harvesting a patient's peripheral blood mononuclear cells, differentiating them into dendritic cells, and loading them with EBV-specific antigens (such as LMP1, LMP2, or EBNA1). Once reinfused, these antigen-presenting cells activate and expand EBV-specific cytotoxic T lymphocytes (CTLs) in vivo, which then target and destroy EBV-positive tumor cells. This therapeutic approach is being evaluated in clinical trials, including investigator-initiated studies in China, for patients with recurrent or refractory EBV-positive nasopharyngeal carcinoma.
- Other names
- EBV dendritic cell vaccineEpstein-Barr virus-targeted dendritic cell vaccineEBV-specific dendritic cell vaccine
02
Targets
EBNA1 (Epstein-Barr virus latency proteins)Epstein–Barr virus latent membrane protein 2 epitopes
Beyond the preview
Go deeper on EBV-targeted dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-targeted dendritic cell vaccine.